Twinbeech Capital LP Crispr Therapeutics Ag Transaction History
Twinbeech Capital LP
- $4.95 Billion
- Q1 2025
A detailed history of Twinbeech Capital LP transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Twinbeech Capital LP holds 31,578 shares of CRSP stock, worth $1.82 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
31,578Holding current value
$1.82 Million% of portfolio
0.02%Shares
5 transactions
Others Institutions Holding CRSP
# of Institutions
481Shares Held
63.9MCall Options Held
2.16MPut Options Held
1.92M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl10.2MShares$587 Million4.09% of portfolio
-
Capital International Investors Los Angeles, CA6.07MShares$350 Million0.04% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.8MShares$219 Million0.09% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$160 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.54MShares$147 Million1.16% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $4.5B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....